Klaus Vedfelt
- AbbVie (NYSE:ABBV) and ADARx Pharmaceuticals announced on Wednesday a collaboration and license option agreement to develop small interfering RNA therapies for several disease areas, including neuroscience, immunology, and cancer.
- As part of the deal, AbbVie will pay ADARx $335M upfront.
- ADARx will also be eligible for billions more in milestone payments, option fees, and royalties based on future progress and sales.